The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss

Bone

Volumn 60, Issue , 2014, Pages 8-15

  Shinohara, Masahiro ^a   Chang, Betty Y ^b   Buggy, Joseph J ^b   Nagai, Yusuke ^a,c,d   Kodama, Tatsuhiko ^e   Asahara, Hiroshi ^a   Takayanagi, Hiroshi ^a,c,d  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b PHARMACYCLICS INC   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Btk; Ibrutinib; Inflammatory bone destruction; Osteoclast; Osteoporosis

Indexed keywords

BRUTON TYROSINE KINASE; IBRUTINIB; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC SCREENING; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BTK; IBRUTINIB; INFLAMMATORY BONE DESTRUCTION; OSTEOCLAST; OSTEOPOROSIS;

ADMINISTRATION, ORAL; ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RANK LIGAND;

EID: 84890709681     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.11.025     Document Type: Article

References (43)

1. Karsenty G., Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002, 2:389-406.
2. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
3. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
4. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009, 5:667-676.
5. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
6. Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4:638-649.
7. 3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 2005, 208:88-105.
8. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
9. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
10. Schmidt U., Boucheron N., Unger B., Ellmeier W. The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol 2004, 134:65-78.
11. Shinohara M., Koga T., Okamoto K., Sakaguchi S., Arai K., Yasuda H., et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 2008, 132:794-806.
12. Honigberg L.A., Smith A.M., Sirisawad M., Verner E., Loury D., Chang B., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010, 107:13075-13080.
13. Herman S.E., Gordon A.L., Hertlein E., Ramanunni A., Zhang X., Jaglowski S., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
14. Chang B.Y., Huang M.M., Francesco M., Chen J., Sokolove J., Magadala P., et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011, 13:R115.
15. Tai Y.T., Chang B.Y., Kong S.Y., Fulciniti M., Yang G., Calle Y., et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012, 120:1877-1887.
16. Negishi-Koga T., Shinohara M., Komatsu N., Bito H., Kodama T., Friedel R.H., et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011, 17:1473-1480.
17. Shinohara M., Nakamura M., Masuda H., Hirose J., Kadono Y., Iwasawa M., et al. Class IA phosphatidylinositol 3-kinase regulates osteoclastic bone resorption through protein kinase B-mediated vesicle transport. J Bone Miner Res 2012, 27:2464-2475.
18. Tomimori Y., Mori K., Koide M., Nakamichi Y., Ninomiya T., Udagawa N., et al. Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J Bone Miner Res 2009, 24:1194-1205.
19. Ishii K.A., Fumoto T., Iwai K., Takeshita S., Ito M., Shimohata N., et al. Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009, 15:259-266.
20. Bozec A., Bakiri L., Hoebertz A., Eferl R., Schilling A.F., Komnenovic V., et al. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 2008, 454:221-225.
21. Novack D.V., Yin L., Hagen-Stapleton A., Schreiber R.D., Goeddel D.V., Ross F.P., et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med 2003, 198:771-781.
22. Sun-Wada G.H., Wada Y., Futai M. Diverse and essential roles of mammalian vacuolar-type proton pump ATPase: toward the physiological understanding of inside acidic compartments. Biochim Biophys Acta 2004, 1658:106-114.
23. Kornak U., Kasper D., Bosl M.R., Kaiser E., Schweizer M., Schulz A., et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001, 104:205-215.
24. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64:693-702.
25. McHugh K.P., Hodivala-Dilke K., Zheng M.H., Namba N., Lam J., Novack D., et al. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000, 105:433-440.
26. Horne W.C., Sanjay A., Bruzzaniti A., Baron R. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev 2005, 208:106-125.
27. Zou W., Izawa T., Zhu T., Chappel J., Otero K., Monkley S.J., et al. Talin1 and Rap1 are critical for osteoclast function. Mol Cell Biol 2013, 33:830-844.
28. Mahajan S., Ghosh S., Sudbeck E.A., Zheng Y., Downs S., Hupke M., et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 1999, 274:9587-9599.
29. Fernandes M.J., Lachance G., Pare G., Rollet-Labelle E., Naccache P.H. Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases. J Leukoc Biol 2005, 78:524-532.
30. van den Akker E., van Dijk T.B., Schmidt U., Felida L., Beug H., Lowenberg B., et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem 2004, 385:409-413.
31. Uckun F.M., Dibirdik I., Qazi S., Vassilev A., Ma H., Mao C., et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 2007, 15:800-814.
32. Advani R.H., Buggy J.J., Sharman J.P., Smith S.M., Boyd T.E., Grant B., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31:88-94.
33. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
34. Wang M.L., Rule S., Martin P., Goy A., Auer R., Kahl B.S., et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013, 369:507-516.
35. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005, 202:1261-1269.
36. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004, 279:45969-45979.
37. Petro J.B., Rahman S.M., Ballard D.W., Khan W.N. Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement. J Exp Med 2000, 191:1745-1754.
38. Webb C.F., Yamashita Y., Ayers N., Evetts S., Paulin Y., Conley M.E., et al. The transcription factor Bright associates with Bruton's tyrosine kinase, the defective protein in immunodeficiency disease. J Immunol 2000, 165:6956-6965.
39. Mahajan S., Vassilev A., Sun N., Ozer Z., Mao C., Uckun F.M. Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem 2001, 276:31216-31228.
40. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
41. Lacey D.L., Boyle W.J., Simonet W.S., Kostenuik P.J., Dougall W.C., Sullivan J.K., et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012, 11:401-419.
42. Taylor P.C. How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA?. Nat Clin Pract Rheumatol 2009, 5:126-127.
43. Tanaka T., Narazaki M., Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012, 52:199-219.